664 related articles for article (PubMed ID: 30451325)
1. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
2. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
[TBL] [Abstract][Full Text] [Related]
3. D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.
Asero R; Marzano AV; Ferrucci S; Cugno M
Int Arch Allergy Immunol; 2017; 172(1):40-44. PubMed ID: 28219067
[TBL] [Abstract][Full Text] [Related]
4. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
Kitsioulis NA; Xepapadaki P; Roussaki-Schulze AV; Papadopoulos N; Zafiriou E
Int Arch Allergy Immunol; 2017; 172(3):161-166. PubMed ID: 28380487
[TBL] [Abstract][Full Text] [Related]
7. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
8. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
[No Abstract] [Full Text] [Related]
9. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
[TBL] [Abstract][Full Text] [Related]
11. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis.
Ferrer M; Giménez-Arnau A; Saldana D; Janssens N; Balp MM; Khalil S; Risson V
J Allergy Clin Immunol Pract; 2018; 6(4):1191-1197.e5. PubMed ID: 29655772
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
13. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
Asero R
Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
16. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
[TBL] [Abstract][Full Text] [Related]
20. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
